| MeSH term | MeSH ID | Detail |
|---|---|---|
| Insulin Resistance | D007333 | 99 associated lipids |
| Weight Gain | D015430 | 101 associated lipids |
| Glioma | D005910 | 112 associated lipids |
| Hypertension | D006973 | 115 associated lipids |
| Inflammation | D007249 | 119 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
| Hemolysis | D006461 | 131 associated lipids |
| Carcinoma, Hepatocellular | D006528 | 140 associated lipids |
| Edema | D004487 | 152 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Fruman DA et al. | The complex of FK506-binding protein 12 and FK506 inhibits calcineurin phosphatase activity and IgE activation-induced cytokine transcripts, but not exocytosis, in mouse mast cells. | 1995 | J. Immunol. | pmid:7530743 |
| Neuhaus P et al. | Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience. | 1995 | Transplantation | pmid:7530868 |
| Heeckt PF et al. | Functional impairment of enteric smooth muscle and nerves caused by chronic intestinal allograft rejection regresses after FK506 rescue. | 1995 | Transplantation | pmid:7530870 |
| Gruessner RW et al. | A prospective study of FK506 versus CsA and pig ATG in a porcine model of small bowel transplantation. | 1995 | Transplantation | pmid:7530871 |
| Todo S et al. | Abdominal multivisceral transplantation. | 1995 | Transplantation | pmid:7530873 |
| Borel JF and Baumann G | Molecular mechanisms of immunosuppressive agents. | 1994 | Bull. Mem. Acad. R. Med. Belg. | pmid:7531051 |
| Whiting PH | Acute and chronic nephrotoxicity associated with immunosuppressive drugs. | 1994 | Curr. Opin. Nephrol. Hypertens. | pmid:7531104 |
| Chen TS et al. | Microbial transformation of immunosuppressive compounds. IV. Hydroxylation and hemiketal formation of ascomycin (immunomycin) by Streptomyces sp. MA 6970 (ATCC No. 55281). | 1994 | J. Antibiot. | pmid:7531195 |
| Bennett WM et al. | Nephrotoxicity of immunosuppressive drugs. | 1994 | Miner Electrolyte Metab | pmid:7531274 |
| Fukuzaki T et al. | A protocol with FK 506 for inducing unresponsiveness to murine islet allografts. | 1995 | Surgery | pmid:7531371 |
| Sekigawa I et al. | FK506 can inhibit apoptotic cell death induced by the HIV-1 envelope glycoprotein gp120. | 1994 | AIDS | pmid:7531458 |
| Lemster BH et al. | IL-8/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapy. | 1995 | Clin. Exp. Immunol. | pmid:7531627 |
| Timerman AP et al. | Characterization of an exchange reaction between soluble FKBP-12 and the FKBP.ryanodine receptor complex. Modulation by FKBP mutants deficient in peptidyl-prolyl isomerase activity. | 1995 | J. Biol. Chem. | pmid:7531689 |
| Foster CA et al. | Pharmacological modulation of endothelial cell-associated adhesion molecule expression: implications for future treatment of dermatological diseases. | 1994 | J. Dermatol. | pmid:7531725 |
| Richter A et al. | Growth inhibitory effects of FK506 and cyclosporin A independent of inhibition of calcineurin. | 1995 | Biochem. Pharmacol. | pmid:7531976 |
| Cacciarelli TV et al. | Influence of the timing of FK 506 (Tacrolimus) administration on recovery of renal function from warm ischemic injury in rats. | 1994 Oct-Dec | ASAIO J. | pmid:7532042 |
| McCauley J | The nephrotoxicity of FK506 as compared with cyclosporine. | 1993 | Curr. Opin. Nephrol. Hypertens. | pmid:7532089 |
| Ryffel B et al. | Nephrotoxicity of immunosuppressants in rats: comparison of macrolides with cyclosporin. | 1994 Nov-Dec | Exp. Nephrol. | pmid:7532090 |
| Marx SO et al. | Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. | 1995 | Circ. Res. | pmid:7532117 |
| Wolter K et al. | Interaction between FK 506 and clarithromycin in a renal transplant patient. | 1994 | Eur. J. Clin. Pharmacol. | pmid:7532134 |
| Konishi M et al. | Effects of FK506 on surface antigen expression by regenerating thymocytes after sublethal irradiation in the rat. | 1994 | Thymus | pmid:7532330 |
| Shapiro R et al. | A prospective, randomized trial of FK-506 in renal transplantation--a comparison between double- and triple-drug therapy. | 1994 | Clin Transplant | pmid:7532475 |
| Murthy JN et al. | Identification of a 14 kDa FK-506/rapamycin binding immunophilin from calf thymus. | 1994 | Clin. Biochem. | pmid:7532556 |
| Donnelly JG and Soldin SJ | Partial characterization of a 52 kDa CsA/FK506/rapamycin binding protein. | 1994 | Clin. Biochem. | pmid:7532557 |
| Kawai M et al. | Pyrrolidine dithiocarbamate inhibits intercellular adhesion molecule-1 biosynthesis induced by cytokines in human fibroblasts. | 1995 | J. Immunol. | pmid:7532665 |
| Venkataraman L et al. | FK506 inhibits antigen receptor-mediated induction of c-rel in B and T lymphoid cells. | 1995 | J. Exp. Med. | pmid:7532676 |
| Wang CR et al. | T cell receptor-mediated signaling events in CD4+CD8+ thymocytes undergoing thymic selection: requirement of calcineurin activation for thymic positive selection but not negative selection. | 1995 | J. Exp. Med. | pmid:7532685 |
| Dawson VL et al. | Expression of inducible nitric oxide synthase causes delayed neurotoxicity in primary mixed neuronal-glial cortical cultures. | 1994 | Neuropharmacology | pmid:7532825 |
| Surdacka E et al. | [New immunosuppressive drugs in transplantation]. | 1994 | Prz. Lek. | pmid:7532870 |
| Cao W et al. | Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. | 1995 | Transplantation | pmid:7532879 |
| Van Thiel DH et al. | Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. | 1995 | Am. J. Gastroenterol. | pmid:7532912 |
| Morikawa K et al. | Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro. | 1994 | Antimicrob. Agents Chemother. | pmid:7532933 |
| Ning YM and Sanchez ER | Stabilization in vitro of the untransformed glucocorticoid receptor complex of S49 lymphocytes by the immunophilin ligand FK506. | 1995 | J. Steroid Biochem. Mol. Biol. | pmid:7532989 |
| Fruman DA et al. | FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells. | 1995 | Eur. J. Immunol. | pmid:7533090 |
| Cameron AM et al. | Immunophilin FK506 binding protein associated with inositol 1,4,5-trisphosphate receptor modulates calcium flux. | 1995 | Proc. Natl. Acad. Sci. U.S.A. | pmid:7533300 |
| Shapiro R et al. | A prospective randomized trial of FK506-based immunosuppression after renal transplantation. | 1995 | Transplantation | pmid:7533343 |
| Cox KL et al. | An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. | 1995 | Transplantation | pmid:7533344 |
| McDiarmid SV et al. | FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the U.S. Multicenter Trial. | 1995 | Transplantation | pmid:7533345 |
| Jain AB et al. | One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events. | 1995 | Transplant. Proc. | pmid:7533353 |
| Rucay P et al. | FK 506 as treatment of late acute rejection in liver transplant patients. | 1995 | Transplant. Proc. | pmid:7533354 |
| Schwartz M et al. | FK 506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. The US Multicenter FK 506 Dose Optimization. | 1995 | Transplant. Proc. | pmid:7533355 |
| Yasuhara M et al. | Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. | 1995 | Transplant. Proc. | pmid:7533356 |
| Platz KP et al. | OKT3 vs FK 506 rescue management of acute steroid-resistant and chronic rejection. | 1995 | Transplant. Proc. | pmid:7533357 |
| Porayko MK et al. | Comparing nephrotoxicity of FK 506 and cyclosporine regimens after liver transplantation: preliminary results from US Multicenter trial. U.S. Multicenter Liver Study Group. | 1995 | Transplant. Proc. | pmid:7533358 |
| Mueller AR et al. | The superior immunosuppressant according to diagnosis: FK 506 or cyclosporine A. | 1995 | Transplant. Proc. | pmid:7533359 |
| Abouljoud MS et al. | Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine A US Multicenter Trial. US Multicenter Study Group. | 1995 | Transplant. Proc. | pmid:7533360 |
| Bäckman L et al. | Whole-blood and plasma levels of FK 506 after liver transplantation: results from the US Multicenter Trial. FK506 Multicenter Study Group. | 1995 | Transplant. Proc. | pmid:7533361 |
| Söderdahl G et al. | FK 506 improves recovery of bile secretion following orthotopic liver transplantation in man. | 1995 | Transplant. Proc. | pmid:7533362 |
| Mor E et al. | Weight gain and lipid profile changes in liver transplant recipients: long-term results of the American FK506 Multicenter Study. | 1995 | Transplant. Proc. | pmid:7533363 |
| Senninger N et al. | Glucose metabolism following liver transplantation and immunosuppression with cyclosporine A or FK 506. | 1995 | Transplant. Proc. | pmid:7533364 |
| Loss M et al. | Influence of long-term cyclosporine or FK 506 therapy on glucose and lipid metabolism in stable liver graft recipients. | 1995 | Transplant. Proc. | pmid:7533365 |
| Lang T et al. | Distinct patterns of Th2 cytokine production during immune activation in pediatric liver allograft recipients. | 1995 | Transplant. Proc. | pmid:7533367 |
| O'Rourke M et al. | Recovery of delayed-type hypersensitivity following liver transplantation. | 1995 | Transplant. Proc. | pmid:7533369 |
| Gaweco AS et al. | Common and sequential overexpression patterns of T-helper cytokines during acute (cellular) rejection, and correlation of proinflammatory cytokine expression with chronic (ductopenic) rejection of human liver allografts: a study under cyclosporine, FK 506, and quadruple BT 563 immunosuppression. | 1995 | Transplant. Proc. | pmid:7533370 |
| Armstrong VW et al. | Metabolic liver function and lipoprotein metabolism after orthotopic liver transplantation in patients on immunosuppressive therapy with FK 506 or cyclosporine. | 1995 | Transplant. Proc. | pmid:7533371 |
| Martinez OM et al. | Molecular markers of Epstein-Barr virus infection in the circulation of transplant recipients. | 1995 | Transplant. Proc. | pmid:7533372 |
| Langrehr JM et al. | Liver transplantation in hepatitis B surface antigen positive patients with postoperative long-term immunoprophylaxis. | 1995 | Transplant. Proc. | pmid:7533373 |
| Vargas V et al. | Alpha-interferon for acute hepatitis C in liver transplant patients. | 1995 | Transplant. Proc. | pmid:7533374 |
| Barkholt LM et al. | New criteria for diagnosing cytomegalovirus hepatitis in liver transplant patients. | 1995 | Transplant. Proc. | pmid:7533375 |
| Teraoka S et al. | Effect of rescue therapy using FK 506 on relapsing rejection after combined pancreas and kidney transplantation. | 1995 | Transplant. Proc. | pmid:7533381 |
| Fay JW et al. | FK 506-based immunosuppression for prevention of graft versus host disease after unrelated donor marrow transplantation. | 1995 | Transplant. Proc. | pmid:7533383 |
| Murase N et al. | Bone marrow augmentation for heart, liver, and small bowel transplantation: prolongation of graft survival and incidence of graft-versus-host disease. | 1995 | Transplant. Proc. | pmid:7533386 |
| Zeevi A et al. | Serial evaluation of immune profiles of simultaneous bone marrow and whole organ transplant recipients. | 1995 | Transplant. Proc. | pmid:7533388 |
| Watanabe K et al. | Factors influencing long-term operational tolerance in dogs treated with fractionated lymphoid irradiation, donor bone marrow cell infusion and FK506. | 1995 | Transplant. Proc. | pmid:7533389 |
| Wennberg L et al. | Efficacy of various immunosuppressive drugs in preventing pig-to-rat islet xenograft rejection. | 1995 | Transplant. Proc. | pmid:7533391 |
| Tanaka M et al. | Effect of anticomplement agent K-76 COOH in hamster-to-rat and guinea pig-to-rat xenotransplantation. | 1995 | Transplant. Proc. | pmid:7533392 |
| Tsugita M et al. | Prevention of sensitization and hyperacute rejection in liver and heart xenografts by FK 506 plus donor antigens. | 1995 | Transplant. Proc. | pmid:7533393 |
| Sakimoto H et al. | Prolonged survival of hamster-to-rat pancreas xenografts by FK 506 and splenectomy. | 1995 | Transplant. Proc. | pmid:7533394 |
| Celli S et al. | Mechanisms of protection from humoral rejection by a xenografted liver. | 1995 | Transplant. Proc. | pmid:7533395 |
| Kuroki H and Ikuta Y | Nerve regeneration of vascularized rat limb allograft and functional recovery of long-term graft survivals treated by short course of FK 506 or cyclosporine. | 1995 | Transplant. Proc. | pmid:7533405 |
| Ko S et al. | Significance of newly developed liposomal FK 506 in canine liver transplantation. | 1995 | Transplant. Proc. | pmid:7533406 |
| Fukuzaki T et al. | Induction of unresponsiveness to islet allografts with donor spleen cell inoculation followed by a single injection of FK 506. | 1995 | Transplant. Proc. | pmid:7533407 |
| Grochowicz PM et al. | Synergism of castanospermine and FK 506. | 1995 | Transplant. Proc. | pmid:7533408 |
| Tamura K et al. | Inhibition of insulin production by FK 506 is caused at the transcriptional level in pancreatic beta cell when FK BP-12 content is relatively high. | 1995 | Transplant. Proc. | pmid:7533409 |
| Kawano K et al. | Protective effect of FK 506 on hepatic injury following cold ischemic preservation and transplantation: influence on hepatic microcirculation. | 1995 | Transplant. Proc. | pmid:7533410 |
| Tanabe M et al. | Therapeutic synergism between low-dose FK 506 and antimetabolites in rat allogeneic heart transplantation. | 1995 | Transplant. Proc. | pmid:7533411 |
| Masri MA | Comparative study of toxicity and efficacy of cyclosporine, cyclosporine G (OG37), FK 506, and rapamycin in BALB/c mice with fitted skin grafts. | 1995 | Transplant. Proc. | pmid:7533412 |
| Jiang H et al. | Immunosuppressive effects of FK 506 on rat renal allograft survival, in comparison with cyclosporine. | 1995 | Transplant. Proc. | pmid:7533413 |
| Bismuth H | Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group. | 1995 | Transplant. Proc. | pmid:7533415 |
| Ochiai T et al. | Japanese multicenter studies of FK 506 in renal transplantation. Japanese FK 506 Study Group. | 1995 | Transplant. Proc. | pmid:7533419 |
| Saito S et al. | The pattern of rejection and susceptibility to different kinds of immunosuppression after combined liver, duodenum, and pancreas transplantation in swine--immunosuppressive drugs versus ex vivo immunomodulation of the allograft. | 1995 | Transplant. Proc. | pmid:7533420 |
| Tashiro H et al. | Monitoring for engraftment of rat orthotopic liver transplantation by semiquantitative PCR. | 1995 | Transplant. Proc. | pmid:7533421 |
| Shirakata Y et al. | The minimum graft size for successful orthotopic partial liver transplantation in the canine model. | 1995 | Transplant. Proc. | pmid:7533422 |
| Kumano K et al. | Role of endothelin in FK 506-induced renal hypoperfusion in rats. | 1995 | Transplant. Proc. | pmid:7533423 |
| Izutani H et al. | Graft coronary arteriosclerosis in rat heart transplant model with FK 506 short-term administration. | 1995 | Transplant. Proc. | pmid:7533425 |
| Funayama Y et al. | Changes in cell adhesion molecules after small bowel transplantation in rats. | 1995 | Transplant. Proc. | pmid:7533426 |
| Laskow DA et al. | Phase II FK 506 multicenter concentration control study: one-year follow-up. | 1995 | Transplant. Proc. | pmid:7533431 |
| Shapiro R et al. | A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients. | 1995 | Transplant. Proc. | pmid:7533432 |
| Winkler M et al. | Comparison of plasma vs whole blood as matrix for FK 506 drug level monitoring. | 1995 | Transplant. Proc. | pmid:7533433 |
| Sakamoto K et al. | Sodium-losing nephropathy and distal tubular damage of transplant kidneys with FK506 administration. | 1995 | Transplant. Proc. | pmid:7533434 |
| Ochiai T et al. | Phase III study of FK 506 in kidney transplantation. Japanese FK 506 Study Group. | 1995 | Transplant. Proc. | pmid:7533435 |
| Scantlebury VP et al. | Renal transplantation under cyclosporine and FK 506 for hemolytic uremic syndrome. | 1995 | Transplant. Proc. | pmid:7533436 |
| Hanafusa T et al. | Long-term impact of hepatitis virus infection on kidney transplant recipients and a pilot study of the effects of interferon alpha on chronic hepatitis C. | 1995 | Transplant. Proc. | pmid:7533440 |
| Bundick RV et al. | The effect of cyclosporin A, FK506, and rapamycin on the murine chronic graft-versus-host response--an in vivo model of Th2-like activity. | 1995 | Clin. Exp. Immunol. | pmid:7533681 |
| Hirakata Y et al. | Influence of various immunosuppressive agents on the occurrence of endogenous bacteraemia in mice. | 1995 | J. Med. Microbiol. | pmid:7533840 |
| Dawson TM et al. | Nitric oxide: cellular regulation and neuronal injury. | 1994 | Prog. Brain Res. | pmid:7533914 |
| Gregory CR et al. | Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. | 1995 | Transplantation | pmid:7533955 |
| Egawa H et al. | Isolated alkaline phosphatemia following pediatric liver transplantation in the FK506 ERA. | 1995 | Transplantation | pmid:7533958 |
| Gonschior AK et al. | Measurement of blood concentrations of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by h.p.l.c.-MS and microparticle enzyme immunoassay (MEIA). | 1994 | Br J Clin Pharmacol | pmid:7534100 |
| Molenaar JC | [Transplantation of the small intestine]. | 1995 | Ned Tijdschr Geneeskd | pmid:7534380 |